Leader of the Turkish pharmaceutical industry Abdi ?brahim, which has established Abdi ?brahim Remede Pharma (A?RP) in Algeria, continues its activities in the region at full speed. Having put into effect the most up-to-date plant investment in the country, Abdi ?brahim collaborated with Biocon, the leading biopharmaceutical company of the region, to launch the first biosimilar product in Algeria, an insulin market worth 300 million-USD. BasalogOne™ is a type of basal insulin which provides an efficacious and safe control of the blood sugar level for a period of 24 hours with no salient peaks. The product is administered once daily subcutaneously to adult patients with type 2 diabetes needing long-acting insulin for hyperglycemia control, adults with Type 1 diabetes, and 6+ pediatric patients.